SAN DIEGO, Nov. 19, 2025 /PRNewswire/ — Ventoux Biosciences, a patient-founded biotechnology company developing therapies for immune-fibrotic diseases, today announced a research program that will explore the therapeutic potential of Ventoux’s lead compound, VEN-201, in translational…
Click here to view original post
Click Here to Publish/Feature Your Company or Product News with Biotech Networks
